Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 15/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983940 | 0.84 | GPR119 (0.48) | CHRM3CHRM2CHRM1KMT2A | |
| SCHEMBL4014578 | 0.84 | CHRM3 (0.57) | CHRM3BCHEACHE | |
| SCHEMBL22484519 | 0.79 | CHRM2 (0.70) | CHRM3CHRM2CHRM1KMT2A | |
| SCHEMBL27623158 | 0.77 | PKM (0.47) | KDM4E | |
| SCHEMBL21088423 | 0.76 | CHRM2 (0.70) | CHRM3CHRM2CHRM1BCHEALDH1A1 | |
| SCHEMBL13398667 | 0.76 | CHRM2 (0.70) | CHRM3CHRM2CHRM1BCHEALDH1A1 | |
| SCHEMBL3976480 | 0.74 | SCD (0.56) | — | |
| SCHEMBL13423819 | 0.74 | CHRM3 (0.48) | CHRM3CHRM2CHRM1 | |
| SCHEMBL6667431 | 0.72 | ACHE (0.57) | CHRM3POLBKMT2AKDM4EALDH1A1 | |
| SCHEMBL23997341 | 0.72 | HPGD (0.51) | POLBKMT2AKDM4EALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074094-A1 | SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS | Pfizer Limited (GB) | 2009-07-01 | — | — | EP | disclosed |
| US-20080090873-A1 | Sulfonamide derivatives | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| WO-2008041095-A1 | SULFONAMIDE DERIVATIVES AS ADRENERGIC AGONISTS AND MUSCARINIC ANTAGONISTS | PFIZER LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090873-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, STS | CHRM3 2453/4885CHRM2 2874/4885CHRM1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.